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a1-Antitrypsin Deficiency and
Susceptibility to Lung Disease
by Hugh E. Evans* and Nora Bognacki*
al-Antitrypsin (AAT), the major component ofa,-globulin, is capable ofinhibiting proteolytic enzymes
in polymorphonuclear leukocytes (PMN) and pulmonary alveolar macrophages (PAM). AAT is ubiqui-
tously distributed in body fluids and tissues. It is a glycoprotein synthesized in the liver with a molecular
weight of50,000 daltons, a half-life of3-6 days, and a sedimentation constant of3.3 S. Enzymes inhibited
include elastase, collagnenase, thrombin, kallikrein, and chymotrypsin. Serum AAT concentration is
determined by multiple codominant alleles. The normal phenotype is M, the most severe deficiency state,
Z; intermediate levels are associated with the MZ phenotype. Ethnicity is a major factor in determining
phenotypic prevalence. The homozygous Z state occurs in 1/4000-1/8000 Caucasians.
Numerous disease processes, mainly involving lungs and liver, have been associated with AAT defi-
ciency. Establishing an unequivocal etiologic relationship, however, between AAT deficiency and lung
disease has been difficult. Studies in this area have varied widely in the number of individuals included,
whether phenotypic analysis, or only quantitative determinations, were carried out, in the range of
clinical and pulmonary function studies performed and whether the population was community or hospi-
tal based. Other confounding variables include the degree of industrial exposure, cigarette smoking, a
history of childhood lung disease, and levels of proteolytic enzymes in PAMs and PMNs.
It has been estimated that about 80%o of those with homozygous Z phenotype will develop obstructive
pulmonary disease. The prevalence of lung disease in other non-M phenotypes, especially among
heterozygotes is uncertain. Those investigations which support, and others which refute, an association
will be reviewed.
Further investigations, especially those emphasizing levels ofproteolytic enzymes, are needed to clarify
the interrelationship of these variant phenotypes, environmental risks and the predisposition to chronic
obstructive lung disease.
Background
a1-Antitrypsin (AAT) is the major component of
a,-globulin. It is capable of inhibiting proteolytic
enzymes in polymorphonuclear leukocytes (PMNs)
and pulmonary alveolar macrophages. Its concen-
tration is determined by about 30 codominant al-
leles. There are five other serum proteins such as
a2-macroglobulin, which also inhibit proteolytic en-
zymes, but these are of lesser importance, unless
AAT is deficient. The capacity to inhibit enzymes is
ubiquitously distributed in all body fluids and tis-
sues and is found widely at all levels of the
phylogenetic scale. Even leguminous plants such as
cabbage, lettuce, and soya bean have inhibitory
capacity. ATT is found in polymorphonuclear
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leukocytes, platelets, and bronchial lining. En-
zymes inhibited by ATT include chymotrypsin,
thrombin, collagenase, kallikrein, and elastase.
AAT is a glycoprotein synthesized in the liver with
a molecular weight of 50,000 daltons. It has a brief
half-life, 3-6 days, and a sedimentation constant of
3.3 S. The normal phenotype is designated as M.
The severest deficiences (10% of normal serum
concentration) are associated with the ZZ
phenotype, and intermediate levels are associated
with the MZ phenotype. There are strong ethnic
determinants of allele prevalence. The S allele is
particularly common among individuals ofHispanic
origin. Non-M phenotypes are rarely observed
among blacks. The frequency of the ZZ phenotype
in Caucasians is 1/4000 to 1/8000. There is a rare
homozygous null state in which there is no detecta-
ble AAT.
AAT serum concentration can be estimated by
usingthe Mancini radial immunodiffusion technique
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widely used functional assay measures the capacity
of serum to inhibit a trypsin-substrate interaction.
BAPNA (benzoyl-arginine p-nitroanilide) is the
usual substrate. The anilide is converted to a yellow
aniline dye measured spectrophotometrically. One
milliliter of serum normally inhibits 1.1-2.0 mg of
trypsin. Phenotyping, the definitive laboratory de-
termination is carried out with the Laurell-Fagerhol
2 step immunoelectrophoretic procedure. Other
techniques include isoelectric focusing at pH of
3.0-6.0, agarose electrophoresis at a pH of8.6, and
immunofixation.
On liver biopsy, diastase-resistant, PAS-positive
globules are typically observed among those with
ZZ, MZ, S, and possibly other phenotypes. Elec-
tron microscopic examination shows these as
amorphous material distending the cisterna of en-
doplasmic reticulum of the mitochondria (1).
Pathogenesis
What is the evidence for a pathogenetic role of
a,1-antitrypsin deficiency in pulmonary disease? The
principal concept is that a homeostatic balance
exists between proteolytic enzymes located within
polymorphonuclear leukocytes (PMNs) or pulmo-
nary alveolar macrophages (PAMs) and circulating
a,-antitrypsin, or comparable enzyme inhibitors
within the lungs themselves. There is no question
that proteolytic enzymes can induce various lung
diseases, at least under certain conditions. For
example, emphysema has been induced in hamsters
using papain and in dogs with PMN derived en-
zymes (2). Newly developed household detergents
contain maxatase and alcalase, enzymes derived
from B. subtilis. Their inhalation has led to the de-
velopment of asthma-like conditions among some
housewives and industrial workers. There are
numerous other examples of enzyme-induced lung
disease.
It is known that AAT and related proteins form
complexes with various enzymes. It is also known
that a1-antitrypsin can be localized to the mem-
branes of PAM cells by immunofluorescent tech-
nique (Dr. Allen Cohen) (3). Among individuals
with serum inhibitor deficiency, those with normal
levels ofPMN esterase tend to have emphysema, in
contrast to those with subnormal concentrations of
PMN esterases who are spared the disease (4).
There may be a synergistic effect between the
number of cigarettes smoked, elastase-like activity
in PMNs, and decreased AAT levels in the de-
velopment of chronic obstructive pulmonary dis-
ease (COPD) (5). Moreover, cigarette smoke re-
duced AAT inhibition of pancreatic and leukocytic
elastase (6). A recent report (7) however, suggested
that the absolute level of proteolytic enzyme in
pulmonary alveolar macrophage is not in itself a
determinant of emphysema. Administration of
aerosolized AAT may prevent papain-induced em-
physema in hamsters (8). It has been shown that
leukocytes are selectively sequestered in the basal
portions of the lung, which is the site of maximum
involvement in COPD associated with AAT defi-
ciency. That is, perfusion and ventilation are par-
ticularly reduced at the lung bases. Cigarette smok-
ers have more PAM cells and each cell has more
proteolytic capacity than is the case for nonsmok-
ers. Therefore, numerous types of experimental
data support the view that a1-antitrypsin deficiency
is a cause ofCOPD, although none provide absolute
proof. Moreover, pathogenetic mechanisms opera-
tive for diseases of other organ systems (intestinal,
hepatic, collagen vascular) are not elucidated by the
studies mentioned.
AAT is an acute-phase reactant and is increased
in various infections, tumors, myocardial infarc-
tions, pregnancy, estrogen administration, and
typhoid vaccine in similarfashion to the erythrocyte
sedimentation rate. There is a nongenetically de-
termined deficiency in serum AAT levels in respi-
ratory distress syndrome ofnewborns (9). A similar
decrease may precede renal homograft rejection.
Phenotypic Variants and Lung
Disease
The association of the ZZ deficiency state and
COPD is well described. A familial form of em-
physema involving males and females equally, with
onset in early adult life has been identified. How-
ever, even in this case, the time ofonset and sever-
ity ofdisease are widely variable. In some cases, no
lung disease at all develops and the individual lives
into the sixth or seventh decade, especially if not
exposed to respiratory irritants (10). About 80% of
ZZ individuals will develop COPD, 10-15% develop
cirrhosis during infancy, and an occasional child, or
adult will have both lung and liver disease.
The relationship of the most common heterozy-
gote state, MZ, and lung disease is controversial. In
evaluating each study concerning this problem, one
must consider the nature and size of the patient
population and of the laboratory methods used. In
some investigations, patients in hospitals were
studied, others focused on people in the commu-
nity. The age range of the subjects, their smoking
habits, their degree of exposure to environmental
pollutants varied widely in different investigations.
Burrows (1/) has called attention to the importance
ofchildhood lung disease as a major determinant of
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thus far has considered this variable. Attempts to
find an association of variant phenotypes with
asthma or cystic fibrosis in children have been un-
successful. However, studies of subsets of asthma,
such as steroid-dependent or nonatopic groups have
shown a relationship. This suggests that AAT defi-
ciency states might be related to certain subtypes of
adisease even though there was no association with
the overall condition. Another problem is that the
range of pulmonary function testing is not uniform
among the various reports. Some have been limited
to simple tests of large airway obstruction, others
have included more extensive studies. Several re-
ports have been based on quantitative mea-
surements of serum AAT only. The authors as-
sumed that those subjects with levels below a cer-
tain value had a genetically determined deficiency.
This assumption cannot be supported by data, in-
cluding our own, which show substantial overlap of
values in heterozygous subjects with levels seen in
MM subjects. Conversely, numerous conditions are
associated with elevated AAT levels, and hence, a
heterozygote could at least temporarily have a value
in the normal range. The concentration of elastase
and other enzymes in PMNs and PAMs may also be
under genetic control and may contribute to the de-
velopment of emphysema. Measurement of con-
centrations ofthese enzymes has not been included
in previous population studies. It is therefore dif-
ficult to judge the role of these confounding vari-
ables in evaluating the possible association of
heterozygote deficiency with lung disease.
One can readily divide the published investiga-
tions into two categories. Those which demonstrate
an association of MZ, or other heterozygote state
with lung disease, or abnormal lung function, and
those which show no such association. For exam-
ple, of three abstracts submitted to the American
Thoracic Society in 1977, dealing with industrial
workers in Canada, two showed no differences
between heterozygotes and MM subjects regarding
abnormal lung function tests (12-14). The third
showed an association of increased risk of COPD
with prolonged employment in a granary among
cigarette smokers (15).
There have been several investigations which
strongly support the association of the MZ
phenotype with obstructive lung disease. An exces-
sive proportion of this phenotype was observed
among two groups of patients in West Germany
with chronic obstructive lung disease. There were
either hospitalized patients, or those retired from
workbecause ofthis disease. The control group was
comprised of blood donors. The prevalence of the
MS phenotype was also higher among the patients
but the trend was not statistically significant (16).
An earlier study by Kueppers showed that
heterozygotes comprised 25.5% of patients with
COPD (25 of98) but only 22 of 188 healthy controls
(p < 0.01) (17). Lieberman was perhaps the first to
suggest such an association, finding 17-18% inci-
dence of heterozygotes in COPD compared with
only 4% in controls (18). However, that initial study
wasbased onquantitativedeterminations oftrypsin in-
hibitory activity without phenotyping. In a later
study he suggested that cigarette smoking enhanced
the risk. A study from Toronto suggested an in-
creased risk of COPD in hospitalized cases related
to the MZ phenotype. By combining several series
with their own, they found this trend to be highly
significant (19). Decreased vital capacity and elec-
trocardiographic changes, suggesting right ven-
tricular abnormalities, were found in a small group,
11 subjects in Warsaw, Poland who were identified
as heterozygotes by quantitative testing only (20).
Abnormalities in MZ subjects with ventilation
scanning have been shown by other groups such as
Fallat (21) and Kanner (22).
Heterozygote (MZ) children have shown statisti-
cally significant differences in forced expiratory
flow rates, and increased frequency dependent
characteristics of total pulmonary resistance when
compared with MM controls (23). These findings
are comparable to those observed in MZ adults.
In contrast, Talamo found no difference in MZ
and MS prevalence in patients with COPD com-
pared with controls (24). This was confirmed in sev-
eral subsequent studies by other investigators. For
example, a long-term, large-scale community sur-
vey in Tucson showed no difference in respiratory
symptoms, disease, or ventilatory function (FEVy/
FVC, and FEF75) related to three major phenotype
groups, M, MS, and MZ. Similarly there were no
differences in the rates of deterioration of function
with age or smoking (25). Similar results were re-
ported by this group usingonly quantitative analysis
of a1-antitrypsin (26). In the intervening years,
other groups likewise concluded that there was no
correlation demonstrable between the MZ
phenotype group and COPD. In a survey of 500
adults in Rochester, Webb, et al. (27) showed no
significant abnormalities of pulmonary function
among those with variant phenotypes compared
with controls. A similar observation had been made
by Welch's group in Oklahoma (28).
Other Pulmonary Diseases
There are three other possible areas of associa-
tion of pulmonary disease with AAT deficiency:
byssinosis, cadmium exposure, and tuberculosis.
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Cadmium chloride given to mice reduces plasma
antitryptic activity (29, 30). Industrial workers ex-
posed to cadmium over a long period of time have
an increased incidence of emphysema (31). Cad-
mium concentrations in emphasematous lungs are
higher than those ofnormal lungs. It is also known
that cadmium accumulates in the human body as a
consequence of cigarette smoking. However, there
is no direct evidence for a role ofAAT deficiency in
this condition.
In unpublished studies ofsmall numbers ofcotton
mill workers with byssinosis in South Carolina a
high prevalence of MZ and ZZ phenotypes have
been found (Dr. Robert Allen, personal communi-
cation).
AAT levels were significantly decreased in cases
ofactive pulmonary tuberculosis in Athens, Greece
(32). There was a trend toward increased preva-
lence ofS and Z alleles, but the sample size was too
small to permit analysis. Prior reports showed
either normal or elevated values of AAT in tuber-
culosis.
Future Studies
The epidemiologic studies reviewed have not led
to definitive conclusions regarding the possible in-
teraction of variant phenotypes of AAT, industrial
pollutants and the prevalence of airway disease.
The number and range of relevant variables which
must be considered in designing future studies are
formidable. The size ofthe populations required to
establish significant differences in the occurrence of
pulmonary disease may also be substantial. Studies
ofchronic disease in adults are necessarily compli-
cated by the existence ofprior illnesses, and this is
especially so with lung disorders. Childhood and
even neonatal disease, may contribute to pulmo-
nary problems in laterlife. Hence, populations to be
studied would require screening for these factors.
The age, sex, and height ofthe subjects, extent and
duration of exposure to pollutants, including
cigarette smoke, assays of various inhibitors in
serum and of enzymes in PAM and PMNs, tests of
pulmonary function, and extent of lung disease are
examples. Some ofthese are difficult to express in
quantitative terms. For example the number of
"pack-years" of cigarettes smoked, and recollec-
tion of prior health history may be inaccurate.
An alternative strategy may be provided by pro-
spective studies of prevalence of pulmonary and
other disease among various phenotypic groups
starting with the neonatal period. This would reduce
the number of variables but necessarily would
exclude the role ofindustrial exposure. In any case,
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FIGURE 1. Relationship ofinhibitors, enzymes, and environment.
an epidemiologic approach may be expensive, time
consuming, complex and may not add further in-
sights. In contrast, basic investigations continue to
yield valuable information regarding the nature of
the proteolytic enzymes and their interaction with
inhibitors. Studies at this level may be more pro-
ductive than epidemiological approaches.
Summary
This subject concerns the complex interrelation-
ship ofa genetically determined protein deficiency,
enzymes which are inhibited by that protein, en-
vironmental challenges such as cigarette smoke and
industrial pollutants, and the occurrence of
obstructive lung disease (Fig. 1). Unequivocal es-
tablishment of an etiological role for AAT defi-
ciency, expecially of intermediate degree, has
proven to be difficult. Confounding variables such
as enzyme concentration in PMN and PAMs, dura-
tion of exposure to potential environmental
hazards, differences in laboratory methods utilized
in measuring AAT and in studying pulmonary func-
tion all require investigation. The definitive study,
incorporating all ofthese and other factors, has yet
to be conducted.
No single, clear-cut conclusion can be drawn
from analysis of present studies. In those circum-
stances in which heterozygotes appear to be predis-
posed to COPD, phenotypic screening ofthe popu-
lation at potential risk, such as industrial workers,
may be appropriate. Conversely, in conditions in
which no association is demonstrated, such
screening would not be justified. Perhaps, the best
one can do is to suggest a "Scotch verdict"; that is,
the issue of causation is not proven.
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